Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine - United Kingdom
doi 10.1186/1479-5876-10-148
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Nanobody Activation Immunotherapeutic That Selectively Destroys HER2-Positive Breast Cancer Cells

ChemBioChem
Organic ChemistryBiochemistryMolecular MedicineMolecular Biology
2015English

Copolymer Micelles Function as pH-responsive Nanocarriers to Enhance the Cytotoxicity of a HER2 Aptamer in HER2-positive Breast Cancer Cells

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term

Breast Cancer Research
Cancer ResearchOncology
2012English

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy